Literature DB >> 9744334

Decreased benzodiazepine receptor binding in Machado-Joseph disease.

M Ishibashi1, T Sakai, T Matsuishi, Y Yonekura, Y Yamashita, T Abe, Y Ohnishi, N Hayabuchi.   

Abstract

UNLABELLED: Benzodiazepine receptor binding was assessed in four Japanese men with Machado-Joseph disease.
METHODS: The distribution of benzodiazepine receptors was measured by radionuclide imaging (SPECT) after intravenous administration of 123I-iomazenil (Ro 16-0154).
RESULTS: SPECT demonstrated decreased binding throughout the cerebral cortex and cerebellum in all patients. Binding potential (receptor concentration x affinity) was diffusely decreased in cerebral cortex, thalamus, striatum and cerebellum compared with control subjects, suggesting that GABAergic function may be decreased globally in these patients. Cerebral blood flow was largely normal, and no cerebral cortical atrophy was evident on MRI.
CONCLUSION: Iodine-123-iomazenil SPECT may become a potent method for detecting impairment of the cerebral cortex even before brain perfusion SPECT or MRI can reveal early abnormalities.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9744334

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

1.  High-dose zolpidem withdrawal seizure in a patient with spinocerebellar ataxia.

Authors:  Cheng-Chen Chang; Wen-Fang Wang
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Repeated Mesenchymal Stromal Cell Treatment Sustainably Alleviates Machado-Joseph Disease.

Authors:  Catarina Oliveira Miranda; Adriana Marcelo; Teresa Pereira Silva; João Barata; Ana Vasconcelos-Ferreira; Dina Pereira; Clévio Nóbrega; Sónia Duarte; Inês Barros; Joana Alves; José Sereno; Lorena Itatí Petrella; João Castelhano; Vitor Hugo Paiva; Paulo Rodrigues-Santos; Vera Alves; Isabel Nunes-Correia; Rui Jorge Nobre; Célia Gomes; Miguel Castelo-Branco; Luís Pereira de Almeida
Journal:  Mol Ther       Date:  2018-07-12       Impact factor: 11.454

Review 3.  Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development.

Authors:  Meng-Ling Chen; Chih-Chun Lin; Liana S Rosenthal; Puneet Opal; Sheng-Han Kuo
Journal:  J Neurol Sci       Date:  2021-04-01       Impact factor: 3.181

Review 4.  Spinocerebellar ataxia clinical trials: opportunities and challenges.

Authors:  Sarah M Brooker; Chandrakanth Reddy Edamakanti; Sara M Akasha; Sheng-Han Kuo; Puneet Opal
Journal:  Ann Clin Transl Neurol       Date:  2021-05-21       Impact factor: 4.511

5.  Assessment of Sleep Spindle Density among Genetically Positive Spinocerebellar Ataxias Types 1, 2, and 3 Patients.

Authors:  Doniparthi Venkata Seshagiri; Ragasudha Botta; Arun Sasidharan; Pramod Kumar Pal; Sanjeev Jain; Ravi Yadav; Bindu M Kutty
Journal:  Ann Neurosci       Date:  2018-03-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.